key: cord-0858433-sg55s5nv authors: Gomez‐Mayordomo, Victor; Montero‐Escribano, Paloma; Matías‐Guiu, Jordi A; González‐García, Nuria; Porta‐Etessam, Jesús; Matías‐Guiu, Jorge title: Clinical exacerbation of SARS‐CoV2 infection after fingolimod withdrawal date: 2020-07-09 journal: J Med Virol DOI: 10.1002/jmv.26279 sha: 715caacc86622baf09cebcc31cd1ec3fd386b735 doc_id: 858433 cord_uid: sg55s5nv The role of disease‐modifying therapies in patients with autoimmune disorders during SARS‐CoV2 infection is controversial. Immunocompromised patients could have a more severe COVID‐19 disease, due to the absence of an adequate immune response against the SARS‐CoV‐2. However, therapies that act on immune response could play a protective role by dampening the cytokine release syndrome. Fingolimod is a drug used for immune therapy in patients with Multiple Sclerosis (MS) through the sequestration of activated lymphocytes in the lymph nodes. We report the case of a 57‐year‐old man with relapsing‐remitting MS treated with fingolimod that showed a reactivation of COVID‐19 with signs of hyperinflammation syndrome after fingolimod withdrawal. Our case suggests that discontinuation of fingolimod during COVID‐19 could imply a worsening of SARS‐CoV2 infection. This article is protected by copyright. All rights reserved. one hand, it could be helpful since it increases the number of circulating lymphocytes and this should improve the defense against the viral infection; but on the other hand, it could also be harmful by increasing the risk of cytokine storm. We describe a case in which a significant worsening of COVID-19 was observed in temporal association with the withdrawal of the drug. We report a 57-year-old man with a diagnosis of relapsing-remitting MS since 1996. He started disease-modifying treatment with interferon beta 1-a, which was switched by Blood tests showed elevated C-reactive protein (12.83 mg/dL [normal range: <0.50]) and lymphopenia (500/ µL). Chest X-ray was unremarkable ( Figure 1: A) , but a fracture of the sixth thoracic vertebra was confirmed. The real-time PCR for SARS-CoV-2 from a nasopharyngeal swab was positive, and the patient was started with hydroxychloroquine for 7 days. FNG was maintained, and during the following three weeks, he persisted with intermittent fever, but no respiratory complications (pO 2 82 mmHg, pCO 2 35 mmHg) and normal chest radiographs (Figure 1: B, C) . Because of the risk of spinal instability, he underwent back surgery on April 18, without complications. Two days later, FNG was discontinued due to low lymphocyte count (100/µL). After a week (day 30 since symptom onset), lymphocytes increased (800/µL), but the patient progressively developed fever (38.5ºC) and dyspnea, requiring oxygen via was discontinued due to a low number of lymphocytes, but did not show clinical changes (14) . In the third case, the patient worsened after fingolimod withdrawal, but was controlled with an interleukin 6 inhibitor drug (16) . It is interesting to compare the number of circulating lymphocytes at the time of FNG withdrawal. It shows how the worsening occurs in those cases where the number was lower, suggesting a greater influx of lymphocytes sequestered into the bloodstream. Hypothetically, it could be explained because of an increase of circulating viral load or a greater immune activity (table 1) . Because some immunosuppressive drugs have been suggested as a potential treatment in COVID-19 in order to prevent or treat cytokine storm 18 , our case may support the idea of maintaining FNG in patients with MS presenting mild forms of COVID-19. In addition, our case may suggest that FNG discontinuation during the active infection may worsen COVID-19. Our report suggests that FNG withdrawal could trigger worsening of the clinical situation of COVID-19, that could be transient (19) and probably suggests the withdrawal of this drug should be done though gradual dose reduction (e.g. alternating days) while monitoring lymphocyte counts to avoid a rapid increase. Additionally, this case seems to suggest a potential beneficial effect of FNG through lymphocyte sequestration, which may be of interest in other situations that affect COVID-19. However, further research is necessary to confirm these preliminary findings and clarify the best management in patients with MS developing COVID-19 infection. The COVID-19 pandemic and the use of MS disease-modifying therapies Two coronaviruses isolated from central nervous system tissue of two multiple sclerosis patients Should We Expect Neurological Symptoms in the SARS-CoV-2 Epidemic? Anti-CD20 Immunosuppressive Disease-Modifying Therapies and COVID-19 Anti-CD20 and COVID-19 in Multiple Sclerosis and Related Disorders: A Case Series of 60 Patients From Madrid, Spain Potential COVID-19 infection in patients with severe multiple sclerosis treated with alemtuzumab Rebound Syndrome in Patients With Multiple Sclerosis After Cessation of Fingolimod Treatment Fingolimod Treatment Rebound Syndrome in Patients with Multiple Sclerosis After Cessation of Fingolimod Treatment Rebound relapses after ceasing another disease-modifying treatment in patients with multiple sclerosis: are there lessons to be learned? Dexamethasone in the management of COVID-19 The underpinning biology relating to multiple sclerosis disease modifying treatments during the COVID-19 pandemic The 'Field Hypothesis': rebound activity after stopping disease-modifying therapies Dysregulation of sphingosine 1 phosphate receptor-1 (S1P1) signaling and regulatory lymphocyte-dependent immunosuppression in a model of post-fingolimod MS rebound COVID-19 infection in a patient with multiple sclerosis treated with fingolimod A Fine Balance: Immunosuppression and Immunotherapy in a Patient With Multiple Sclerosis and COVID-19 COVID-19: consider IL-6 receptor antagonist for the therapy of cytokine storm syndrome in SARS-CoV-2 infected patients Immunologic Characterization of a Immunosuppressed Multiple Sclerosis Patient That Recovered From SARS-CoV-2 Infection